[go: up one dir, main page]

MX2018007043A - Agentes de contraste dimericos. - Google Patents

Agentes de contraste dimericos.

Info

Publication number
MX2018007043A
MX2018007043A MX2018007043A MX2018007043A MX2018007043A MX 2018007043 A MX2018007043 A MX 2018007043A MX 2018007043 A MX2018007043 A MX 2018007043A MX 2018007043 A MX2018007043 A MX 2018007043A MX 2018007043 A MX2018007043 A MX 2018007043A
Authority
MX
Mexico
Prior art keywords
contrast agents
dimeric contrast
metal ions
dimeric
mri
Prior art date
Application number
MX2018007043A
Other languages
English (en)
Other versions
MX395695B (es
Inventor
Lattuada Luciano
Napolitano Roberta
Boi Valeria
Original Assignee
Bracco Imaging Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Imaging Spa filed Critical Bracco Imaging Spa
Publication of MX2018007043A publication Critical patent/MX2018007043A/es
Publication of MX395695B publication Critical patent/MX395695B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/122—Macromolecular compounds dimers of complexes or complex-forming compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a una nueva clase de macrociclos diméricos capaces de quelar iones metálicos paramagnéticos, sus complejos quelados con iones metálicos, y el uso de los mismos como agentes de contraste, particularmente adecuados para el análisis de imágenes por resonancia magnética (IRM).
MX2018007043A 2015-12-10 2016-12-12 Agentes de contraste diméricos. MX395695B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15199220 2015-12-10
PCT/EP2016/080621 WO2017098044A1 (en) 2015-12-10 2016-12-12 Dimeric contrast agents

Publications (2)

Publication Number Publication Date
MX2018007043A true MX2018007043A (es) 2018-08-15
MX395695B MX395695B (es) 2025-03-25

Family

ID=55027251

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007043A MX395695B (es) 2015-12-10 2016-12-12 Agentes de contraste diméricos.

Country Status (23)

Country Link
US (3) US10407412B2 (es)
EP (2) EP3386954B1 (es)
JP (1) JP6896733B2 (es)
KR (1) KR102703336B1 (es)
CN (1) CN108368067B (es)
AU (1) AU2016368545C1 (es)
BR (1) BR112018010815B1 (es)
CA (1) CA3002897C (es)
DK (2) DK3753929T3 (es)
ES (2) ES2932302T3 (es)
FI (1) FI3753929T3 (es)
HR (2) HRP20210061T1 (es)
HU (2) HUE052680T2 (es)
IL (1) IL259836B (es)
LT (1) LT3386954T (es)
MX (1) MX395695B (es)
PL (2) PL3753929T3 (es)
PT (1) PT3386954T (es)
RU (1) RU2739834C2 (es)
SG (1) SG11201804412SA (es)
SI (2) SI3386954T1 (es)
WO (1) WO2017098044A1 (es)
ZA (1) ZA201802846B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
ES2932302T3 (es) 2015-12-10 2023-01-17 Bracco Imaging Spa Agentes de contraste diméricos
WO2018096082A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
HUE056114T2 (hu) * 2016-12-12 2022-01-28 Bracco Imaging Spa Dimer kontrasztanyagok
AU2019382881B2 (en) 2018-11-23 2025-06-12 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
EP4073045B1 (en) 2019-12-13 2024-03-20 Bracco Imaging SPA Manufacturing of protected do3a
IT202000000922A1 (it) * 2020-01-20 2021-07-20 Cage Chemicals S R L Complessi di ferro e relativi sali come agenti di contrasto per MRI
US12217384B2 (en) 2020-01-29 2025-02-04 University Of Cincinnati Contrast enhancement method for the objects with intrinsic partial volume effect
EP4188912B1 (en) 2020-07-27 2024-07-03 Bracco Imaging SpA Manufacturing of dimeric contrast agents
KR20230116805A (ko) * 2020-12-04 2023-08-04 브라코 이미징 에스.피.에이. 가도테리돌 제조를 위한 제조 방법
CN117412980A (zh) 2021-07-27 2024-01-16 伯拉考成像股份公司 二聚体造影剂的制备
CN117440959A (zh) * 2021-07-27 2024-01-23 伯拉考成像股份公司 用于制造钆络合物溶液的方法
CN118401500A (zh) 2021-12-14 2024-07-26 伯拉考成像股份公司 制备包含钆络合物的二聚体大环中间体的混合物的方法
JP2024546845A (ja) 2021-12-14 2024-12-26 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 二量体造影剤の製造
WO2024074648A1 (en) 2022-10-07 2024-04-11 Bracco Imaging Spa Precipitation and isolation of gadolinium complex

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
DE3625417C2 (de) * 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
US5132409A (en) 1987-01-12 1992-07-21 Bracco Industria Chimica S.P.A. Macrocyclic chelating agents and chelates thereof
GB9320277D0 (en) * 1993-10-01 1993-11-17 Nycomed Salutar Inc Chelants
DE4009119A1 (de) 1990-03-19 1991-09-26 Schering Ag 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4035760A1 (de) 1990-11-08 1992-05-14 Schering Ag Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4115789A1 (de) 1991-05-10 1992-11-12 Schering Ag Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4318369C1 (de) * 1993-05-28 1995-02-09 Schering Ag Verwendung von makrocyclischen Metallkomplexen als Temperatursonden
GB9318550D0 (en) * 1993-09-07 1993-10-20 Nycomed Salutar Inc Chelants
IT1291624B1 (it) 1997-04-18 1999-01-11 Bracco Spa Chelati complessi di metalli paramagnetici a bassa tossicita'
DE19719033C1 (de) 1997-04-29 1999-01-28 Schering Ag Ionenpaare, Verfahren zu ihrer Herstellung und ihre Verwendung als Kontrastmittel
IT1292128B1 (it) 1997-06-11 1999-01-25 Bracco Spa Processo per la preparazione di chelanti macrociclici e loro chelati con ioni metallici paramagnetici
EP1032430A2 (en) * 1997-11-17 2000-09-06 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
DE19849465A1 (de) * 1998-10-21 2000-04-27 Schering Ag Dimere Ionenpaare, Verfahren zu ihrer Herstellung und ihre Verwendung als Kontrastmittel
DE10117242C1 (de) * 2001-04-06 2002-05-16 Schering Ag Unsymmetrische dimere Metallkomplexe, Liganden für diese Metallkomplexe, Verfahren zu deren Herstellung, Arzneimittel bzw. Diagnosemittel, die die Metallkomplexe enthalten, insbesondere Kontrastmittel
US6852854B1 (en) * 2002-10-01 2005-02-08 Psiloquest Inc. Preformed carboxylated active ester for labeling biomolecules
US7208140B2 (en) 2003-02-19 2007-04-24 Schering Aktiengesellschaft Trimeric macrocyclic substituted benzene derivatives
EP1765812B1 (en) * 2004-07-02 2009-04-29 Bracco Imaging S.p.A Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (mri) which contain a chelating moiety with polyhydroxylated substituents
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
RU2425831C2 (ru) * 2005-12-02 2011-08-10 Джи-И Хелткер АС Мультимерные контрастные агенты для магнитного резонанса
CL2008001002A1 (es) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
EP2149567A1 (en) 2008-07-18 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Cyclic polyamines for binding phosphatidylserine
EP2457594A1 (en) * 2010-11-05 2012-05-30 Bracco Imaging S.p.A Cest systems exhibiting a concentration independent responsiveness
US9315524B2 (en) 2012-05-07 2016-04-19 Kumar Ranjan Bhushan Magnetic resonance imaging agents for calcification
CN102727911B (zh) 2012-07-09 2013-07-24 中国科学院长春应用化学研究所 双氨基聚乙二醇修饰的顺磁性金属配合物磁共振成像造影剂
US9155804B2 (en) 2012-09-26 2015-10-13 General Electric Company Contrast enhancement agents and method of use thereof
WO2015023979A1 (en) 2013-08-16 2015-02-19 Equip, Llc Discrete peg constructs
ES2932302T3 (es) * 2015-12-10 2023-01-17 Bracco Imaging Spa Agentes de contraste diméricos

Also Published As

Publication number Publication date
DK3386954T3 (da) 2021-02-15
AU2016368545C1 (en) 2021-01-07
PT3386954T (pt) 2021-01-07
AU2016368545A1 (en) 2018-05-10
US11401262B2 (en) 2022-08-02
LT3386954T (lt) 2021-04-12
IL259836B (en) 2021-07-29
CA3002897C (en) 2022-03-29
US20180362511A1 (en) 2018-12-20
EP3753929A1 (en) 2020-12-23
EP3753929B1 (en) 2022-10-26
US10882849B2 (en) 2021-01-05
HUE052680T2 (hu) 2021-05-28
US20190345142A1 (en) 2019-11-14
US20200331893A9 (en) 2020-10-22
EP3386954B1 (en) 2020-12-02
ZA201802846B (en) 2025-06-25
RU2739834C2 (ru) 2020-12-28
US20210024500A1 (en) 2021-01-28
WO2017098044A1 (en) 2017-06-15
RU2018123572A (ru) 2020-01-13
HRP20210061T1 (hr) 2021-03-05
AU2016368545B2 (en) 2020-09-03
CA3002897A1 (en) 2017-06-15
HRP20221451T1 (hr) 2023-02-17
SI3386954T1 (sl) 2021-02-26
EP3386954A1 (en) 2018-10-17
SG11201804412SA (en) 2018-06-28
JP2019501153A (ja) 2019-01-17
BR112018010815A2 (pt) 2018-11-27
KR102703336B1 (ko) 2024-09-06
SI3753929T1 (sl) 2023-01-31
ES2932302T3 (es) 2023-01-17
PL3386954T3 (pl) 2021-06-14
DK3753929T3 (da) 2023-01-23
KR20180090823A (ko) 2018-08-13
ES2843998T3 (es) 2021-07-21
MX395695B (es) 2025-03-25
IL259836A (en) 2018-07-31
NZ741900A (en) 2021-10-29
CN108368067A (zh) 2018-08-03
FI3753929T3 (fi) 2023-01-31
JP6896733B2 (ja) 2021-06-30
RU2018123572A3 (es) 2020-02-10
US10407412B2 (en) 2019-09-10
PL3753929T3 (pl) 2023-03-13
CN108368067B (zh) 2022-04-29
HUE060536T2 (hu) 2023-03-28
BR112018010815B1 (pt) 2022-05-17

Similar Documents

Publication Publication Date Title
MX2018007043A (es) Agentes de contraste dimericos.
CL2017003083A1 (es) Nuevos compuestos de quelato de gadolinio para usar en imágenes de resonancia magnética
MX2017002940A (es) Aumento ferromagnético para formación de imagenes por resonancia magnética.
CO2023012137A2 (es) Nuevo agente de contraste para utilizar en imágenes por resonancia magnética
BR112018011541A2 (pt) agentes de contraste
MX2018016082A (es) Compuestos quelatos.
GB201518430D0 (en) Magnet apparatus for generating high gradient magnetic field
UY37500A (es) Nuevos compuestos de quelato de gadolinio con alta relaxividad para usar en la obtencion de imagenes por resonancia magnetica
MX2019007595A (es) Compuestos de quelato de manganeso basados en tetra-azabiciclo-macrociclos adecuados como agentes de toma de imagenes mri.
EP3512570A4 (en) INNOVATIVE LIPOSOMAL GADOLINIUM (GD) CONTRASTANT NMRX FOR T1-MRI
MX2022002586A (es) Isomeros de quelatos de manganeso.
BR112017017959A2 (pt) derivados de ácido etilenodiaminatetraacético bis(amida) e seus respectivos complexos com íon mn(ii) para uso como agente de contraste de mri.
UY35544A (es) Complejos de bis azainositol hafnio para adquisición de imágenes por rayos x
RU2013116765A (ru) 5-МЕТИЛ-6-НИТРО-7-ОКСО-4,7-ДИГИДРО-1,2,4-ТРИАЗОЛО[1,5-α]ПИРИМИДИНИД l-АРГИНИНИЯ МОНОГИДРАТ
GB201709715D0 (en) Contrast agents for magnetic resonance imaging